Pursuits
AstraZeneca, American Eagle, Nebraska: Intellectual Property
This article is for subscribers only.
Dec. 4 (Bloomberg) -- AstraZeneca Plc will soon learnwhether it faces billions of dollars in damages for paying ageneric-drug maker to delay copies of its blockbuster heartburntablet Nexium in the first trial since the U.S. Supreme Courtruled consumers can sue over such pay-to-delay deals.
The case against AstraZeneca and the Indian generics makerRanbaxy Laboratories Ltd. challenges a 2008 settlement of apatent lawsuit that stalled sales of a cheaper version of Nexiumin the U.S. until AstraZeneca’s patents expired last May.